Form 8-K - Current report:
SEC Accession No. 0001731122-25-000935
Filing Date
2025-07-03
Accepted
2025-07-03 17:25:40
Documents
14
Period of Report
2025-07-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6684_8-k.htm   iXBRL 8-K 32550
2 EXHIBIT 10.1 e6684_ex10-1.htm EX-10.1 17861
3 EXHIBIT 10.2 e6684_ex10-2.htm EX-10.2 40556
  Complete submission text file 0001731122-25-000935.txt   272564

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE avxl-20250703.xsd EX-101.SCH 3008
5 XBRL LABEL FILE avxl-20250703_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE avxl-20250703_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT e6684_8-k_htm.xml XML 3687
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 251106434
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)